by Safe RX Compounding | May 23, 2026 | Featured
Interest in next-generation obesity medicines is accelerating rapidly — and so is the online marketplace claiming to sell them. One of the latest examples is retatrutide, an investigational therapy currently being studied in clinical trials but increasingly promoted...
by Safe RX Compounding | May 4, 2026 | Featured
Philip Schneider, MS FASHP FFIP As a pharmacist, my priority is helping patients benefit from medicines, and protect them from harm caused by medicines intended to help them. This week we saw an example of why the oversight of the U.S. Food and Drug Administration...
by Safe RX Compounding | May 4, 2026 | Featured
Media Contact: Lisa McDonald, Vice President of Communications, 202-207-2829 Washington, DC – You can fool some of the people some of the time and all of the people some of the time. But you can’t fool all of the people all the time. On Friday, February 6, the Food...
by Safe RX Compounding | Apr 9, 2026 | Featured
As demand grows for high-profile therapies like GLP-1 medications, a parallel market of compounded versions has expanded rapidly. While compounding plays an important and appropriate role in certain patient specific clinical situations, recent developments are raising...
by Safe RX Compounding | Feb 18, 2026 | Featured
Caught in the Middle? Not! As a pharmacist, one could imagine that the issue of compounding a medicine for which there is widespread patient need would be an opportunity, not a problem. Pharmacists of a “certain age” spent a lot of time when we were in pharmacy...
by Safe RX Compounding | Jan 19, 2026 | Featured
January 15, 2026 | Julian Gill The company declined to provide its full response to the FDA but said it “addressed the agency’s feedback and will continue to regularly communicate with FDA about any remaining commitments.” … The FDA inspected the larger...
